After a stunning summer surge, shares of Alder Biopharmaceuticals (ALDR) have become a headache for its owners, tumbling over 32% in the past three months. Upcoming results about its migraine drug will hopefully ease their pain, said the immunotherapy company’s CEO Dr. Randall Schatzman. 'We’ve just initiated the last stage of our clinical trial campaign and the first of our pivotal trials. But we’ve got a couple of other trials that are ongoing that we are just finishing up now,' said Schatzman. 'We will be reporting data on those in the first quarter of 2016. I think those will be significant in terms of highlighting the better way to treat these patients.' Alder’s drug is based on a molecule which the company refers to as ALD403. It is a monoclonal antibody to a small neuropeptide transmitter called calcitonin gene-related peptide, or CGRP. Schatzman said it is an important molecule in terms of both the initiation and the propagation of the signal that actually starts a migraine and advances that into the central nervous system. 'There are 36 million migraine sufferers in the United State alone today and about 18 million of those are candidates for the Alder drug,' said Schatzman, adding that that the $428 million the company has in cash will get it through the next significant set of studies allow it to apply for licensure with the FDA.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.